cancers (Coussens and Werb, 1996; Chambers and Matrisian, 1997) , and the resulting imbalance between MMPs and their specific inhibitors has been shown to play an important role in tumour growth and invasion (Stetler Stevenson et al, 1993; Chambers and Matrisian, 1997) . In cultured human melanoma cells elevated expression of MMP-1, MMP-2, and MMP-9 has been shown to be correlated with migration and invasion Ray and Stetler Stevenson, 1995; Durko et al, 1997) . Increased expression of TIMP-1, TIMP-2 and TIMP-3 was able to inhibit these processes (Khokha et al, 1992; Montgomery et al, 1994; Imren et al, 1996; Ahonen et al, 1998; Valente et al, 1998) . In human melanocytic lesions a positive correlation between tumour progression and MMP-2 expression level was demonstrated (Vaisanen et al, 1996 (Vaisanen et al, , 1998 . Increased expression of MMP-9, on the other hand, was found mainly in radial growth phase of primary melanoma, indicating that MMP-9 expression correlates with early invasion of melanoma (van den Oord et al, 1997) .
In the present study we investigated the expression of MMP-1, -2, -3, -9, TIMP-1 and TIMP-2 mRNA and protein in a previously described xenograft model consisting of eight human melanoma cell lines with different metastatic capacity after subcutaneous (s.c.) injection into nude mice (van Muijen et al, 1991a (van Muijen et al, , 1991b Westphal et al, 1997) . We show for the first time that increased expression of activated MMP-2 is correlated with melanoma progression, indicating that activated MMP-2 may be required for melanoma invasion and metastasis.
MATERIALS AND METHODS

Cell lines and culture conditions
Melanoma cell lines 530, 1F6, MV1, M14, Mel57, 1F6m, MV3 and BLM have been described previously (van Muijen et al, 1991a (van Muijen et al, , 1991b . All cell lines were derived from surgically removed human metastases, and form local tumours after s.c. injection into nude mice. The xenografts differ in growth rate and capacity to form spontaneous lung metastases, as described previously (Westphal et al, 1997) (Table 1) . Melanoma cell line M24met was kindly provided by Dr B Mueller (The Scripps Institute, La Jolla, CA, USA), and served as a positive control for MMP-1 expression. Human fibrosarcoma cell line HT1080 (American Type Culture Collection, Rockville, MD, USA) served as a positive control for MMP-9 expression. All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (Biowhittaker, MD, USA), supplemented with 10% fetal calf serum (FCS) (Integro, Zaandam, The Netherlands) and gentamycin (40 µg ml -1 , Gibco-BRL, Gaithersburg, MD, USA) in an atmosphere of 95% humidified air and 5% carbon dioxide at 37°C. Cells were detached from tissue-culture flasks with 0.05% trypsin, 0.02% EDTA and 0.1% glucose in phosphate-buffered saline (PBS) for 2 min at 37°C.
Xenografts in nude mice and rats
Human melanoma cell lines were xenografted in BALB/c nu/nu mice kept under aseptic conditions according to NIH guidelines. A (Grant et al, 1996) Factor Primer sequences Product size
total of 3-5 × 10 6 cells of human melanoma cell lines 530, 1F6, Mel57, 1F6m, MV3 and BLM were injected s.c. into the flank of nude mice. In order to be able to use mouse monoclonal antibodies for immunohistochemistry, 1F6 and BLM xenografts were also grown in nude rats. The animals were sacrificed when the tumour had a diameter of approximately 1 cm. Parts of the tumours were snap-frozen and stored in liquid nitrogen.
RNA isolation
Total RNA from each cell line was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Typically, 1 × 10 7 cells were used for each isolation, yielding 50-100 µg RNA. For RNA extraction from tissue samples, frozen sections from xenografts derived from melanoma cell lines were used. Total RNA was isolated after disrupting at least one 20-µm frozen section in 1 ml RNAzolB TM (Campro, Veenendaal, The Netherlands) using a pestle. Melanin and DNA were removed from RNA samples using the RNeasy kit.
RT-PCR analysis
A total of 0.5 µg of RNA was reverse-transcribed with the 1st Strand cDNA Synthesis Kit for reverse transcription polymerase chain reaction (RT-PCR) (Boehringer Mannheim, Penzberg, Germany) using random hexadeoxynucleotide primers according to the manufacturer's instructions. One microlitre aliquots of the reverse-transcribed cDNA was subjected to PCR, using PCR buffer IV (20 mM (NH 4 ) 2 SO 4 , 75 mM Tris-HCl pH 9, 0.1% Tween) 0.2 M dNTPs, 2 pmoles of each primer, 1.5 mM magnesium chloride and 0.15 units of Thermoperfectplus DNA polymerase (Integro, Zaandam, The Netherlands). Water was added to a final volume of 25 µl. Each PCR was performed for 30 cycles (45 s at 94°C, 1 min at 59°C, 1 min 30 s at 72°C), preceeded by a denaturation step at 94°C for 3 min, and terminated with an elongation step at 72°C for 5 min. PCR products were visualized on 2% agarose gels containing ethidium bromide. As positive control for the RT-PCR procedure we used β 2 -microglobulin (β 2 -m). Incubations in which cDNA was omitted were used as negative controls. The PCR procedure was performed at least twice for each sample. The sequences of the human specific PCR primers are given in Table 2 .
Northern blot analysis
Aliquots of 5 µg of total RNA extracted from each cell line were electrophoresed on a 1% agarose gel containing MOPS/ paraformaldehyde and transferred to a nylon membrane (Boehringer Mannheim) by capillary blotting in 20 × standard saline citrate (SSC) according to standard protocols. Levels of 28S and 18S RNA were used as a control for RNA integrity and loading consistency. RNA was fixed to the membrane by baking for 30 min at 120°C. Probes for MMP-1 and MMP-2 were 1.4 kb and 2.6 kb cDNA fragments (gifts from Dr R Hanemaaijer (Gaubius Laboratory IVVO-TNO, Leiden, The Netherlands)), cloned in Bluescript KS vector and isolated from overnight cultures with the Wizard TM Miniprep Kit (Promega, Madison, WI, USA). DIG-labelled DNA probes were produced by performing PCR on cloned DNA fragments in the presence of 0.7 mM DIGlabelled dUTP in PCR DIG labelling mix (Boehringer Mannheim). DNA probes were purified with the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany) following the manufacturer's instructions. Blots were hybridized overnight at 50°C at a probe concentration of 40 ng ml -1 in Easyhyb hybridization buffer (Boehringer Mannheim). Blots were washed twice for 5 min at room temperature in 2 × SSC 0.1% sodium dodecyl sulphate (SDS), once in 0.5 × SSC 0.1% SDS at 68°C for 15 min, and finally in 0.1 × SSC 0.1% SDS for 15 min at 68°C. The membranes were developed by chemiluminescence detection with CSPD or CDP-Star (Boehringer Mannheim), and exposed to Kodak X-Omat-AR film.
Western blot analysis
Serum-free conditioned medium (SFCM) was generated by washing cells three times with PBS, followed by incubation overnight in serum-free medium. SFCM derived from 1 × 10 7 cells from each cell line was used. Western blot analysis was performed according to standard protocols. Briefly, 12 µl samples of 10 times concentrated (Centricon 10 microconcentrator; Amicon, Beverly, MA, USA) SFCM were run on 10% polyacrylamide gel. Samples were incubated for 5 min at 95°C in the presence of 10% β-mercaptoethanol prior to electrophoresis. After electrophoresis, samples were electroblotted onto nitrocellulose (Schleier & Schuell, Dassel, Germany). Blots were blocked for 30 min in blocking solution (Boehringer Mannheim) at room temperature and then incubated overnight with 1 µg ml -1 of primary antibody in blocking solution. After washing with PBS 0.05% Tween-20, membranes were incubated for 2 h at room temperature with a rabbit anti-mouse peroxidase-labelled secondary antibody (Dako, Denmark) in blocking solution. After additional washes, binding of peroxidase-labelled antibody was visualized by chemiluminescence (Boehringer Mannheim), according to the manufacturer's protocol.
Gelatin zymography
Zymography was performed according to standard protocols. Aliquots of unconcentrated SFCM (5 µl) were diluted 1:1 in sample-buffer (62.5 mM Tris-HCl (pH 6.8), 8.8% glycerol, 2% (w/v) SDS, 0.05% bromophenol blue). After heating at 60°C for 20 min, samples were electrophoresed at 4°C on a 7.5% SDSpolyacrylamide gel containing 0.5 mg ml -1 gelatin. After electrophoresis, gels were washed three times in 2.5% Triton X-100 for 10 min to remove SDS. After rinsing twice in substrate buffer (50 mM Tris-HCl, pH 7.8, containing 5 mM calcium chloride and 0.1% Triton X-100), the gels were incubated at 37°C for 18 h in the same buffer under gentle agitation. Gels were stained for 45 min in 40% methanol 10% glacial acetic acid containing 0.1% (w/v) Coomassie brilliant blue R250 and re-stained in the same solution without Coomassie brilliant blue. Activation of MMP-2 and MMP-9 was achieved by incubating samples before zymography with 1 mM p-aminophenylmercuric acetate (APMA) at 37°C for 2 h. Latent proMMP-2 (M r 66 000) and proMMP-9 (M r 92 000) as well as activated MMP-2 (M r 62 000) and MMP-9 (M r 84 000) were identified by comparing them to known gelatinolytic activity from conditioned medium from HT1080 cells (Sato et al, 1994) and control samples containing MMP-2 and MMP-9 protein (Oncogene Research Products, Cambridge, MA, USA) with and without APMA pretreatment. For zymography analysis of xenografts, 4 serial tissue cryostat sections (10-µm) were homogenized in 4 × sample-buffer, centifuged for 1 min at 10 000 g, and pellets were incubated at 37°C for 30 min. Samples were mixed with distilled water (1:1) and heated at 60°C for 20 min. After centrifugation (1 min, 10 000 g) pellets were discarded and supernatants were subjected to zymographic analysis. Zymography was performed at least twice for each sample.
Antibodies
For Western blot analysis mouse monoclonal antibodies (mAbs) (Oncogene Research Products, Cambridge, MA, USA) against MMP-1 (clone 41-1E5), MMP-2 (clone 42-5D11), MMP-3 (clone 55-2A4), MMP-9 (clone 56-2A4), TIMP-1 (clone 7-6C1) and TIMP-2 (clone T2-101) were used. For immunohistochemistry a rabbit polyclonal antibody against human MMP-2 (# AB809, Chemicon International Inc, Temecula, CA, USA), sheep polyclonal antibodies against MMP-3 (# PH112, The Binding Site Limited, Birmingham, UK), MMP-9 (# PH163, The Binding Site Limited, Birmingham, UK), and mouse monoclonal antibodies (Oncogene Research Products, Cambridge, MA, USA) against MMP-1 (clone 41-1E5), TIMP-1 (clone 7-6C1) and TIMP-2 (clone T2-101) were used. A polyclonal rabbit antibody against human u-PA (Dako, Carpinteria, CA, USA) (Ferrier et al, 1998) was used as positive control.
Immunohistochemistry
For immunohistochemistry 4-µm cryostat serial sections of xenograft lesions were used. At least three different xenografts per cell line were analysed. Sections were fixed for 10 min at room temperature in aceton with 0.15% hydrogen peroxide to inactivate endogenous peroxidase, followed by incubation overnight with primary antibodies in humidified chamber at 4°C. Subsequent steps were performed at room temperature. Prior to incubation with a biotinylated goat anti-rabbit, horse anti-mouse or goat antisheep secondary antibodies (Vector Laboratories, Burlingame, CA, USA) for 30 min, the avidin-biotin blocking kit (Vector Laboratories) was used according to the manufacturer's protocol. Forty-five minutes after addition of the avidin-biotin-peroxidase complex (Vectastain Elitekit, Vector Laboratories), sections were developed with amino-ethyl carbazol (AEC), and counterstained with Meyer's haematoxylin. An incubation where the first antibody was omitted served as negative control.
RESULTS
We investigated the expression of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2 in a xenograft model consisting of eight human melanoma cell lines with different metastatic behaviour after s.c. inoculation into nude mice. Cell lines 530 and 1F6 are non-or sporadically metastasizing, whereas MV1, M14, Mel57, 1F6m, MV3 and BLM are frequently metastasizing. Of these six lines, MV3 and BLM tumours grow faster, and generate lung metastases much sooner compared to the other four cell lines (Westphal et al, 1997) (Table 1) .
MMP and TIMP mRNA in human melanoma cell lines
RT-PCR analysis detected MMP-1, MMP-2, TIMP-1 and TIMP-2 mRNA in all melanoma cell lines. MMP-3 mRNA was only produced by the very aggressive cell lines MV3 and BLM and, remarkably, also by the non-metastatic cell line 530. MMP-9 mRNA, on the other hand, was not detectable in any cell line; the 390-bp PCR band represents amplified DNA instead of RNA. A control RT reaction for MMP-9 without reverse transcriptase was performed (data not shown). The results of the RT-PCR analysis are shown in Figure 1 . In order to make a quantitative comparison of MMP-1 and MMP-2 mRNA levels, we performed Northern blot analysis. MMP-1 mRNA levels were too low to be detected in Northern blotting, whereas MMP-2 mRNA levels were clearly elevated in the highly metastatic cell lines MV3 and BLM (Figure 2 ).
MMP and TIMP protein in human melanoma cell lines
MMP and TIMP protein levels were determined by Western blot analysis of 10 × concentrated SFCM derived from 1 × 10 7 cells (Figure 3 ). In agreement with our Northern blot results, MMP-1 protein was undetectable in our panel of cell lines. MMP-2 protein could be detected in all cell lines, but markedly increased in the highly metastatic cell lines MV3 and BLM. MMP-3 protein was present in SFCM of the cell lines MV3 and BLM but, despite MMP-3 mRNA expression, MMP-3 protein was not detectable in SFCM from cell line 530. In agreement with the results on mRNA no MMP-9 protein was detectable in any cell line. Western blots for TIMP-1 and TIMP-2 showed protein expression in all cell lines. Although the expression levels of TIMP-1 and TIMP-2 protein markedly differed among cell lines, there was no evident correlation with metastatic capacity in the xenograft model. Activation status of MMP-2 was studied by zymography analysis of unconcentrated SFCM. Pretreatment of SFCM with p-APMA has been shown to induce the autocatalytic removal of the amino-terminal domain of the proMMPs, resulting in conversion to the active form. The latent proMMP-2 was detectable in all cell lines, but expression of functionally active MMP-2 was restricted to the highly metastatic cell lines MV3 and BLM. 
MMP and TIMP mRNA in melanoma xenografts
Frozen tissue sections from melanoma xenograft lesions derived from cell lines 530, Mel57, 1F6m, MV3 and BLM were used to determine mRNA expression of MMPs and TIMPs in vivo ( Figure  5 ). The RT-PCR data of 1F6, MV1 and M14 are not shown, because melanin present in the xenografts copurified with the RNA, and caused strong inhibition of the RT-reaction (Westphal et al, manuscript in preparation) . Expression of MMP-1 mRNA was found in MV3 and BLM xenografts and, to a lesser extent, in 530 tumours. MMP-2 mRNA was detectable in 1F6m, MV3 and BLM xenografts. MMP-3 and TIMP-1 mRNA were not expressed in any xenografts. A very low MMP-9 mRNA expression was observed in 530 xenografts. TIMP-2 mRNA was detectable in all samples.
MMP and TIMP protein in melanoma xenografts
We used immunohistochemistry to investigate the expression of MMP and TIMP proteins in vivo. Mice xenografts from cell lines 530, Mel57, 1F6m, MV3 and BLM were stained with polyclonal antibodies. Rat xenografts from 1F6 and BLM were used for immunohistochemistry with mouse monoclonal antibodies. A moderate granular cytoplasmatic staining for MMP-1 was detectable in all tumour cells in 1F6 and BLM xenografts. In these lesions the stromal septa separating tumour cell nests showed also a strong immunoreactivity (data not shown). Tumour cells in 530, 1F6 and Mel57 xenografts were MMP-2-negative, whereas some fibroblasts and tumour surrounding stromal cells were MMP-2-positive ( Figure 6A ). In 1F6m xenografts a moderate granular and cytoplasmatic staining of tumour cells was found. A heterogeneous strong granular cytoplasmatic staining pattern was observed in tumour cells in MV3 and BLM xenografts ( Figure 6B ). Remarkably, immunoreactivity of tumour cells increased at the growth or invasive front of 1F6m, MV3 and BLM xenografts ( Figure 6C ). No staining of tumour cells was observed for MMP-3, MMP-9 and TIMP-1, whereas macrophages of mouse origin surrounding the tumours showed a strong immunoreactivity for both MMP-3 and MMP-9 ( Figure 6D) . A strong immunoreactivity against TIMP-1 was found in blood vessels of rat tissue adjacent to tumours ( Figure 6E ). In all studied xenografts tumour cells were positive for TIMP-2 protein. The tumour cells in the periphery of necrotic areas stained stronger ( Figure 6F ). Finally, we performed zymography to determine the activation status of MMP-2 protein expression in xenografts. The latent form of MMP-2 (M r 66 000) was detectable in all studied xenografts. Expression of MMP-2 protein in 530 and Mel57 xenografts is due to mouse origin. In these lesions we found a strong immunoreactivity for MMP-2 only in macrophages surrounding the tumours. The M r 62 000 band representing the activated form of MMP-2, however, showed increased expression levels in MV3 and BLM xenografts (Figure 7 ).
DISCUSSION
Cutaneous melanoma is characterized by a high capacity for invasion and metastasis. In this process degradation of the ECM and basement membranes by proteolytic enzymes is an essential step, in which MMPs play an important role (Stetler Stevenson et al, 1993; Mueller, 1996) . Overexpression of MMP-1, MMP-2 and MMP-9 has been implicated in the migration and invasion of melanoma cells Ray and Stetler Stevenson, 1995; Durko et al, 1997) . The relative contribution of these enzymes to melanoma invasion and metastasis, however, is not fully understood. We used a well-defined human melanoma xenograft model to investigate the expression profiles of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2, and their correlation to melanoma progression.
Compared with the cultured cell lines where MMP-1 protein was undetectable, expression was up-regulated in xenograft lesions. A moderate staining for MMP-1 was found in xenografts of both the non-metastatic cell line 1F6 and the highly metastatic cell line BLM. A strong immunoreactivity for MMP-1 was detectable in stromal septa surrounding the tumour nests, indicating that host mechanisms may be involved in up-regulated expression of MMP-1 in vivo. It has been demonstrated that expression of MMPs in tumour surrounding stromal cells is an important factor in the process of tumour progression . In another study expression of MMP-1 has been shown to correlate with invasive capacity of melanomas (Woolley et al, 1980) . In agreement with this, Durko et al (1997) showed that invasion of human melanoma cells through type VI collagen and a reconstituted basement membrane (Matrigel) was dependent on expression of MMP-1.
An increased expression of MMP-2 has been shown to be associated with tumour progression in several tumour types (Nomura et al, 1995; Lambert et al, 1998) . In melanocytic lesions, a correlation between MMP-2 protein expression and decreased architectural organization, increased atypia, and haematogenous metastasis was described (Vaisanen et al, 1996) . In another study by the same group (Vaisanen et al, 1998) , a positive correlation between high level of MMP-2 protein expression and poor prognosis in melanoma patients was found. Consistent with this, we found clearly elevated expression level of MMP-2 mRNA and protein in the most aggressive cell lines MV3 and BLM as well as in the corresponding xenografts. The discrepancy in the levels of MMP-2 mRNA in vitro, as determined by RT-PCR and Northern blot is most likely due to the fact that the results of RT-PCR represent the end-point of the reaction, making a quantitative comparison of samples impossible. Since the ability of a tumour to activate MMP-2 may be more important than MMP-2 expression per se, we also studied MMP-2 activation status. We found that activated MMP-2 of tumour cells was restricted to the most aggressive cell lines MV3 and BLM, both in vitro and in vivo. In line with this, activation of MMP-2 was shown to correlate with malignant progression in brain tumours (Yamamoto et al, 1996) , lung (Tokuraku et al, 1995) and gastric carcinomas (Nomura et al, 1995) . The specific mechanism of proMMP-2 activation is not fully understood. It has been demonstrated that increased expression of MT1-MMP results in activation of MMP-2 on the cell surface, which is required for cell invasion when localized to invadopodia of human melanoma cells (Nakahara et al, 1997) . MMP-2 activity, however, is also regulated by the amount of TIMP-2 present (Butler et al, 1998) . On one hand, TIMP-2 may act as a specific inhibitor of MMP-2, and has been shown to inhibit tumour growth and tumour cell invasion (Montgomery et al, 1994; Imren et al, 1996; Valente et al, 1998) . On the other hand, TIMP-2 may be directly involved in MMP-2 activation by forming a complex with MT1-MMP that functions as a receptor for MMP-2 at the cell surface (Strongin et al, 1995; Butler et al, 1998; Zucker et al, 1998) . A coordinated expression of MMP-2, MT1-MMP and TIMP-2 resulting in an activation of MMP-2 was also reported to be correlated with malignant progression in other human cancers (Kanayama et al, 1998; Lambert et al, 1998) . We found TIMP-2 mRNA and protein expressed in all cell lines in vitro and in vivo. Whether in our xenograft model TIMP-2 acts as a MMP-2 inhibitor, as a MMP-2 co-activator, or both, remains to be determined.
The role of MMP-9 in melanoma progression is unclear. Whereas we found virtually no expression of MMP-9 mRNA and protein in tumour cells in vitro and in vivo, MMP-9 expression was described in seven melanoma cell lines derived from advanced stage melanoma, but not from early stage melanoma . In contrast, van den Oord et al (1997) found MMP-9 expression in human melanoma cells in the radial growth phase of primary melanoma with thickness < 1.6 mm, but not in melanoma metastases. In line with this, the lack of MMP-9 expression in our panel of cell lines may be attributed to the fact that all lines are derived from human melanoma metastases. Our data on MMP-9 expression taken together with several reports based on immunohistochemistry and in situ hybridization indicate that MMP-9 may not expressed by tumour cells but predominantly by tumour surrounding stromal cells (Heppner et al, 1996; Nielsen et al, 1996; Sugiura et al, 1998) .
To the best of our knowledge the expression profile of MMP-3 in melanoma has not yet been studied. MMP-3 protein was shown to be expressed by the highly metastatic cell lines MV3 and BLM, suggesting a possible role for MMP-3 in tumour cell invasion and metastasis. In agreement with this, Sreenath et al (1992) showed that high levels of MMP-3 expression were associated with metastatic potential of transformed rat embryo cells. In xenograft lesions we found no expression of MMP-3 protein in tumour cells, whereas a strong immunoreactivity was observed in macrophages and tumour surrounding stromal cells. A similar stromal cell expression pattern has also been described in other tumour types as colorectal cancer (Newell et al, 1994) . Our observations on MMP-3 and MMP-9 expression by macrophages and fibroblasts supports the possible involvement of these cells in melanoma progression. Studies on MMP expression by stromal cells in human melanoma are currently in progress.
TIMP-1 serves as a regulatory element of MMP-9 activation (Gomez et al, 1997; Nagase, 1997) , and increased expression of TIMP-1 inhibits tumour growth, invasion and metastasis of melanoma cells in vitro and in vivo (Khokha et al, 1992; Khokha, 1994) . In our study we found that TIMP-1 was expressed by all cell lines, but no expression was detectable in xenografts, indicating that TIMP-1 expression is down-regulated in vivo. Therefore, the role of this molecule in tumour progression in our xenograft model appears to be limited.
Although the specific role of the different MMPs in tumour progression, and the specific activation mechanism of the MMPs in vivo still remains unclear, our study shows that an increased expression of activated MMP-2 correlates with metastatic behaviour in our xenograft model. Our data taken together with previous studies strongly implicate an important role for activated MMP-2 in melanoma progression. Studies on specifically blocking MMP-2 activity may lead to novel strategies in the systemic therapy of malignant melanoma.
